Notes:
To further investigate the efficacy and safety of aspirin and warfarin, the SPAF II study continued to follow patients who had been randomized to aspirin or warfarin in the original SPAF trial. They also re-randomized patients originally on placebo and recruited 419 new patients (most older than 75 years) and randomized these patients to receive warfarin or aspirin. The group that was over 75 years of age was followed for a mean of 2.0 years, while the less than 75 year-old group was followed for a mean of 3.1 years.

Back

Contents

Next

Acknowledgments:
The content of this presentation was prepared by Dr. Gregory Albers of the Stanford Stroke Center.